RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A
RA Capital Management, L.P. and affiliated funds, including Peter Kolchinsky and Rajeev Shah, filed a Schedule 13G/A stating they beneficially own 4,897,182 ordinary shares of GH Research PLC (GHRS), or 7.1% of the class. The filing cites 68,642,287 shares outstanding as of an issuer Form 6-K filed Aug. 6, 2026.
How this was made
The 30-second read
Why it matters
A disclosed 7.1% stake can shift market perception of shareholder base and potential influence, but the text does not indicate a change in strategy, governance demands, or a transaction.
Market read
Traders may monitor for follow-on amendments (e.g., intent changes) or activist signals, but the article itself is primarily a regulatory stake disclosure.
What to watch
The filing includes disclaimers about group status and beneficial ownership mechanics; without stated plans, traders should avoid assuming control or board influence changes.
Background
The article is a Schedule 13G/A ownership disclosure by RA Capital Management and affiliated funds regarding GH Research PLC ordinary shares.
Ticker impact
RA Capital Management filed a Schedule 13G/A disclosing it beneficially owns 4,897,182 GH Research PLC shares, or 7.1% of the class.
Near-term price impact is likely limited unless follow-on actions (board/strategy changes) emerge; watch for subsequent 13D/13G amendments or activist commentary.
The article provides a fresh ownership disclosure (7.1%) but no accompanying intent to change strategy, no deal, and no fundamental update to GH Research PLC.
Market effects
Could modestly increase attention on small-cap biotech/healthcare research issuers where institutional stake disclosures sometimes precede activism, but no sector-wide signal is provided.
No clear regional spillover beyond the issuer’s home market.
Limited, as the disclosure is specific to one foreign issuer and does not describe cross-border transactions.
Counterpoint
A 13G/A can reflect passive or advisory-delegated holdings without activist intent, so the stake may not translate into any near-term corporate action.
Key entities
- issuerGH Research PLC
Foreign issuer whose ordinary shares are subject of the Schedule 13G/A disclosure.
- investorRA Capital Management, L.P.
Reporting person disclosing beneficial ownership of 7.1% via affiliated funds and advisory arrangements.
- fundRA Capital Healthcare Fund, L.P.
Holds 4,768,564 ordinary shares referenced in the filing.
- fundRA Capital Nexus Fund II, L.P.
Holds 128,618 ordinary shares referenced in the filing.
